268 related articles for article (PubMed ID: 31024557)
21. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
22. Cytosolic Receptor Melanoma Differentiation-Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury.
Gesuete R; Christensen SN; Bahjat FR; Packard AE; Stevens SL; Liu M; Salazar AM; Stenzel-Poore MP
Stroke; 2016 Jan; 47(1):262-6. PubMed ID: 26564103
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.
Kende M; Paragas J; Salazar AM
Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774
[TBL] [Abstract][Full Text] [Related]
24. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.
Ammi R; De Waele J; Willemen Y; Van Brussel I; Schrijvers DM; Lion E; Smits EL
Pharmacol Ther; 2015 Feb; 146():120-31. PubMed ID: 25281915
[TBL] [Abstract][Full Text] [Related]
25. Novel antiviral therapeutics to control foot-and-mouth disease.
Dias CC; Moraes MP; Weiss M; Diaz-San Segundo F; Perez-Martin E; Salazar AM; de los Santos T; Grubman MJ
J Interferon Cytokine Res; 2012 Oct; 32(10):462-73. PubMed ID: 22924938
[TBL] [Abstract][Full Text] [Related]
26. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
27. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
28. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM
J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068
[TBL] [Abstract][Full Text] [Related]
29. Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
Awasthi A; Mehrotra S; Bhakuni V; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1997 Jul; 17(7):419-23. PubMed ID: 9243375
[TBL] [Abstract][Full Text] [Related]
30. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
[TBL] [Abstract][Full Text] [Related]
31. Killing of Leishmania donovani amastigotes by poly ICLC in hamsters.
Bhakuni V; Singha UK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Apr; 16(4):321-5. PubMed ID: 9162526
[TBL] [Abstract][Full Text] [Related]
32. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
[TBL] [Abstract][Full Text] [Related]
33. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
Ewel CH; Urba WJ; Kopp WC; Smith JW; Steis RG; Rossio JL; Longo DL; Jones MJ; Alvord WG; Pinsky CM
Cancer Res; 1992 Jun; 52(11):3005-10. PubMed ID: 1591717
[TBL] [Abstract][Full Text] [Related]
34. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
[TBL] [Abstract][Full Text] [Related]
35. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant.
Marques RF; Gimenez AM; Caballero O; Simpson A; Salazar AM; Amino R; Godin S; Gazzinelli RT; Soares IS
Vaccine; 2024 Apr; 42(9):2394-2406. PubMed ID: 38448321
[TBL] [Abstract][Full Text] [Related]
36. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
[TBL] [Abstract][Full Text] [Related]
38. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
39. Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.
Crane LR; Levy HB; Lerner AM
Antimicrob Agents Chemother; 1982 Mar; 21(3):481-5. PubMed ID: 7049075
[TBL] [Abstract][Full Text] [Related]
40. Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate).
Bhakuni V; Kulkarni S; Ali V; Singh UK; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1999 Oct; 19(10):1103-6. PubMed ID: 10547149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
